NAD⁺, Aging, and the Problem With Simple Biomarkers

For several years, NAD⁺ has been one of the most popular molecules in the longevity world. It appears in supplement marketing, biological aging discussions, mitochondrial health programs, and even consumer testing panels.

The story is often presented in a simple way:

NAD⁺ declines with age, lower NAD⁺ means poorer cellular energy, and raising NAD⁺ may help restore youthful function.

There is some biological logic behind this. NAD⁺ is deeply involved in metabolism, mitochondrial function, DNA repair, sirtuin activity, inflammatory regulation, and cellular stress responses. It is not a trivial molecule. But the simplicity of the public narrative has often moved faster than the evidence.

A new study in Nature Metabolism, titled “Human whole-blood NAD⁺ levels do not vary with age or lifestyle interventions,” adds an important correction to the conversation. The authors developed a carefully validated UHPLC–HRMS method to measure NAD⁺ in human whole blood and then tested it across seven independent human cohorts.

Their main finding was striking: whole-blood NAD⁺ levels remained remarkably stable across age, frailty, elite athletic status, exercise, protein-rich diet, and multimodal lifestyle interventions. NAD⁺ increased clearly after nicotinamide riboside supplementation, confirming that the assay could detect direct NAD⁺ precursor effects, but ordinary age and lifestyle differences were not reflected by whole-blood NAD⁺ levels.

This does not mean NAD⁺ biology is unimportant. It means the current hype may be focusing on the wrong layer.

The problem with the simple NAD⁺ story

The common longevity message is often built around a single idea: “More NAD⁺ is better.”

But biology rarely works that way.

A whole-blood NAD⁺ value is a static measurement. It tells us something about the amount of NAD⁺ detected in a specific blood sample under specific laboratory conditions. It does not tell us where NAD⁺ is located, how quickly it turns over, whether NADH is being efficiently oxidized back to NAD⁺, whether mitochondrial electron transport is congested, or whether tissue-specific repair systems are functioning properly.

This distinction matters. A person could have a normal whole-blood NAD⁺ level while still having impaired mitochondrial throughput, redox imbalance, high inflammatory NAD⁺ consumption, altered lactate handling, poor sleep recovery, insulin resistance, or tissue-specific energetic stress.

In other words, the issue may not be simply how much NAD⁺ is present. The more important question may be:

Can the cell maintain the right NAD⁺/NADH balance, in the right compartment, at the right time, under the right physiological demand?

That is a very different question from “Is my blood NAD⁺ high or low?”

Why this study matters

This study may have a large impact because it challenges three assumptions behind the current NAD⁺ hype.

First, it weakens the idea that whole-blood NAD⁺ is a simple biomarker of aging. If older adults, younger adults, elite athletes, and frail older adults can show similar whole-blood NAD⁺ levels, then this marker alone cannot carry the weight often placed on it.

Second, it separates NAD⁺ boosting from biological rejuvenation. Nicotinamide riboside increased blood NAD⁺, but that does not automatically prove improved mitochondrial function, better tissue repair, lower biological age, or restored resilience. It shows that an NAD⁺ precursor changed the measurable blood pool.

Third, the study highlights a major technical issue: sample handling matters. Freezing and thawing can reduce measured NAD⁺, while methanol-based preservation improves stability. This means some earlier findings in the field may need to be interpreted carefully, especially if sample handling was inconsistent.

The message is not that NAD⁺ supplements are useless or that NAD⁺ biology is irrelevant. The message is more subtle and more important:

NAD⁺ is biologically important, but whole-blood NAD⁺ alone may be too buffered, too compartment-insensitive, and too technically fragile to serve as a simple aging or wellness score.

ERM and a better way to think about NAD⁺ biology

The Exposure-Related Malnutrition framework offers a broader way to understand this.

ERM does not view chronic dysfunction as a single deficiency. It views it as a pattern of demand–utilization–allocation mismatch. Under chronic stress, inflammation, poor sleep, metabolic overload, environmental exposure, undernutrition, or repeated recovery failure, the body may keep vital systems running by reallocating resources away from repair, growth, detoxification, immune resolution, and long-term resilience.

From this perspective, NAD⁺ is not simply a “level” to raise. It is part of a dynamic bioenergetic network.

NAD⁺ accepts electrons and becomes NADH. NADH must then be oxidized back to NAD⁺, largely through mitochondrial oxidative phosphorylation. If mitochondrial throughput is constrained — because of inflammation, hypoxia, nutrient mismatch, circadian disruption, excess substrate load, or impaired electron transport capacity — then the problem may become less about absolute NAD⁺ depletion and more about redox congestion.

A useful analogy is traffic flow.

NAD⁺ is not just the number of roads. NADH is not just the number of cars. The real question is whether traffic can move through the system. If the mitochondrial “highway” is congested, adding more vehicles or expanding one reservoir may not solve the bottleneck. The system needs restored flow.

In ERM language, this means we should ask:

Is substrate input exceeding oxidative capacity?

Is NADH being efficiently recycled back to NAD⁺?

Is the cytosol becoming more reductive?

Is mitochondrial throughput limited?

Are repair pathways consuming NAD⁺ faster than it can be regenerated locally?

Are sleep, circadian rhythm, protein intake, micronutrients, inflammation, and stress physiology supporting recovery?

These questions move NAD⁺ biology from supplement hype toward systems biology.

Beyond “boosting NAD⁺”

The next stage of the NAD⁺ conversation should be less about simply raising blood NAD⁺ and more about restoring redox flexibility and compartment-specific function.

That includes mitochondrial NAD⁺/NADH balance, cytosolic lactate–pyruvate dynamics, nuclear NAD⁺ use for DNA repair and chromatin regulation, immune-cell NAD⁺ consumption through inflammatory pathways, and the ability to regenerate NAD⁺ during real physiological demand.

This is where lifestyle interventions may still matter deeply, even if whole-blood NAD⁺ does not change. Exercise may improve mitochondrial throughput. Sleep may reduce substrate pressure and inflammatory activation. Protein and micronutrients may support enzyme systems, tissue repair, and redox buffering. Stress reduction may lower chronic neuroendocrine demand. These effects may not appear as a simple rise in whole-blood NAD⁺, but they may still improve the system’s capacity to use and recycle NAD⁺ effectively.

That is the key lesson.

A stable NAD⁺ level does not mean a stable bioenergetic system. And a higher NAD⁺ level does not automatically mean a healthier one.

A more mature NAD⁺ model

This study should not end interest in NAD⁺. It should refine it.

The field needs to move from:

“How do we raise NAD⁺?”

to:

“How do we restore NAD⁺ cycling, NADH oxidation, mitochondrial throughput, and compartment-specific repair capacity?”

That shift is exactly where the ERM framework becomes useful. ERM helps place NAD⁺ within a larger adaptive system: stress load, nutrient availability, mitochondrial capacity, repair demand, redox balance, and recovery timing.

In this model, NAD⁺ is not a magic molecule. It is a participant in the body’s larger economy of energy, repair, and resilience.

The public conversation around NAD⁺ has been too simple. This new study gives us a reason to make it more honest, more precise, and more physiologically meaningful.

Trętowicz, M. M., Scantlebery, A. M. L., Schomakers, B. V., Eroğlu, K. D., van Weeghel, M., Spek, V., Vinten, K. T., Legon, L., Coskun, E., Millan-Domingo, F., Olaso-Gonzalez, G., Gomez-Cabrera, M. C., Montoro-García, S., Noguera-Navarro, C., van Kuilenburg, A. B. P., Moco, S., van Hattum, J. C., Jørstad, H. T., Benali, M., … Houtkooper, R. H. (2026). Human whole-blood NAD⁺ levels do not vary with age or lifestyle interventions. Nature Metabolism. https://doi.org/10.1038/s42255-026-01537-5